Results 251 to 260 of about 276,897 (341)

Microbial metabolites regulating PD-L1 and checkpoint pathways: translational implications. [PDF]

Ann Med Surg (Lond)
Mehmood MS, Danaf N.
europepmc   +1 more source

Senescence-associated secretory phenotype (SASP) and uterine fibroids: Association with PD-L1 activation and collagen deposition [PDF]

Ahmed S. Saad, Rachel Michel, Mostafa A. Borahay   +2 more
openalex   +1 more source

O030: PD‐L1 up‐regulation and signaling in carcinoma cells by PD‐L1 up‐regulation and signaling in carcinoma cells by P. gingivalis cell wall components [PDF]

, 2018

openalex   +1 more source

Irradiated Tumor Cell‐Derived Microparticles Activate Systemic Anti‐Tumor Immunity via the STING/NLRP3/GSDMD Axis in Neutrophils

Advanced Science, EarlyView.
Radiotherapy induces tumor cells to release microparticles (RT‐MPs) into the circulation. The mitochondrial DNA carried by these RT‐MPs activates the STING/NLRP3/GSDMD axis in splenic neutrophils, triggering IL‐1β secretion. This, in turn, enhances dendritic cell function and facilitates the formation of cytotoxic T lymphocytes, thereby promoting ...
Yan Hu, Jiacheng Wang, Mengjie Che, Zheng Yang, Jingshu Meng, Xiao Yang, Yue Deng, Zhiyuan Zhou, Yijun Wang, Wenwen Wei, Zhanjie Zhang, Bian Wu, You Qin, Kunyu Yang, Honglin Jin, Fang Huang, Yajie Sun, Lu Wen, Chao Wan   +18 more
wiley   +1 more source

Lenvatinib potentiates the antitumor efficacy of combined radiotherapy and PD-L1 blockade in lung adenocarcinoma. [PDF]

Cancer Biol Ther
Liu Y, Xiao L, Nie X, Lyu J, Tang C, Li L, Zhang X, Li T, Huang J, Zhang S.   +9 more
europepmc   +1 more source

Integrative Multi‐Omics Analysis Uncovers Immunological Phenotypes Predictive of Combinatorial Immunotherapy Response in Gastric Cancer

Advanced Science, EarlyView.
Current understanding of gastric cancer immunity remains inadequate, leading to suboptimal immunotherapy outcomes. This study introduces a novel tumor immune microenvironment classification system (Inflamed, Desert, and Excluded), advancing traditional histopathological or molecular subtyping toward a functional immunological framework.
Jianchao Wang, Wenfang Zhang, Jiyang Zhang, Chenhui Zhao, Wei Zhang, Menghan Fang, Fangfang Chen, Zhida Wu, Xiaoya Xu, Ziqing Yu, Qiong Zhu, Yi Shi, Dadong Zhang, Xiaofeng Chen, Gang Chen   +14 more
wiley   +1 more source

Unlocking the mystery of the PD-1/PD-L1 axis: beyond the checkpoint hype. [PDF]

Front Immunol
Desimpel PH, Petit PF, J Van den Eynde B, Zhu J.   +3 more
europepmc   +1 more source

ATG-101 Is a Tetravalent PD-L1×4-1BB Bispecific Antibody That Stimulates Antitumor Immunity through PD-L1 Blockade and PD-L1–Directed 4-1BB Activation [PDF]

Hui Yuwen, Huajing Wang, Tengteng Li, Yijing Ren, Yun-kai Zhang, Peng Chen, Ao Sun, Gang Bian, Bohua Li, David Flowers, Marc Presler, Kalyanasundaram Subramanian, Jia Xue, Jingjing Wang, Kevin Lynch, Jay Mei, Xiaowen He, Bo Shan, Bing Hou   +18 more
openalex   +1 more source

PD-L1 Inhibitor INCB086550 [PDF]

, 2020
openaire   +1 more source

scPER: A Rigorous Computational Approach to Determine Cellular Subtypes in Tumors Aligned With Cancer Phenotypes From Total RNA Sequencing

Advanced Science, EarlyView.
scPER presents an adversarial‐autoencoder framework that deconvolves bulk total RNA‐seq to quantify tumor‐microenvironment cell types and uncover phenotype‐linked subclusters. Across diverse benchmarks, scPER improves accuracy over existing tools.
Bingrui Li, Xiaobo Zhou, Raghu Kalluri
wiley   +1 more source